Aoxing Pharmaceutical Company, Inc. Announces Earnings Results for the Second Quarter and Six Month Periods Ended December 31, 2013
February 19, 2014 at 12:15 pm EST
Share
Aoxing Pharmaceutical Company, Inc. announced earnings results for the second quarter and six month periods ended December 31, 2013. For the quarter, the company's revenues for the three ended December 31, 2013 were $3,466,807, representing a 5% increase over the revenues realized in the comparable periods of fiscal year 2013. The increase in revenue was mainly attributable to the increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Sales of Zhongtongan accounted for 90% of sales during the quarter ended December 31, 2013. The resulting net loss recorded for the three months ended December 31, 2013 was $1,917,469, whereas the company's net loss for the three months ended December 31, 2012 was $3,135,661.
For the six months, the company's revenues for the six months ended December 31, 2013 were $7,043,915, representing a 19% increase over the revenues realized in the comparable periods of fiscal year 2013. The increase in revenue was mainly attributable to the increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Sales of Zhongtongan accounted for 90% of sales during the quarter ended December 31, 2013. The net loss of $4,268,443 for the six months ended December 31, 2013 exceeded the net loss of $3,584,176 recorded in the comparable period of the prior year.
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The Company holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter (OTC) and active pharmaceutical ingredient (API) products. Its products include prescription drugs, such as Tilidine hydrochloride, Zhongtong'an and Humifuse Euphorbia Herb Tablet, and OTC drugs, such as Shanmei Capsule, Shaoshang Tincture, Yiqi Qiangshen Granule, Xiaopiling Granule, Xiongjushangqing Tablet, Juyuansuanbijia Oral Solutions, Longdanxiegan Tablet, Fenka Tablet, Shujinhuoxue Tablet, Fuketiaojing Tablet, Qingnao Jiangya Tablet, Yuanhu Pain Management Tablet, Bushenqiangshen Tablet, Baiziyangxin Pill, Qingguo Pill, Liuweidihuang Pill, Zhibaidihuang Pill, Xiaoyao Pill and Tianwangbuxin Pill.